Tiarnan D Keenan1, Henry E Wiley1, Elvira Agrón1, Mary E Aronow1, William G Christen2, Traci E Clemons3, Emily Y Chew4. 1. Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland. 2. Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 3. The Emmes Corporation, Rockville, Maryland. 4. Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: echew@nei.nih.gov.
Abstract
PURPOSE: To analyze the potential association between aspirin use and progression of age-related macular degeneration (AMD). DESIGN: Two prospective cohort studies within 2 controlled clinical trials of oral supplementation for age-related eye disease. PARTICIPANTS: Age-Related Eye Disease Study (AREDS) participants 55 to 80 years of age and AREDS2 participants 50 to 85 years of age. METHODS: Propensity scores for aspirin use were calculated for AREDS and AREDS2 participants separately by logistic regression. Of the participants without late AMD (geographic atrophy [GA] or neovascular AMD) in either eye at study baseline, aspirin users were matched 1:1 with nonusers by propensity score (separately for AREDS and AREDS2). Proportional hazards regression was performed, adjusting for age, on the matched participants to evaluate associations between aspirin propensity score and progression to late AMD (and its subtypes). MAIN OUTCOME MEASURES: Progression to late AMD on color fundus photographs, graded centrally. RESULTS: Of the 3734 eligible AREDS participants, 1049 (28.1%) were taking aspirin, and of the 2403 eligible AREDS2 participants, 1198 (49.9%) were takingaspirin. After matching by propensity score, the characteristics of the users and nonusers were similar in both studies. Of the 1950 matched AREDS participants and 1694 matched AREDS2 participants, over a median follow-up of 10.1 years and 5.0 years, respectively, the numbers who progressed to late AMD, GA, or neovascular AMD were 454 (23.3%), 345 (17.7%), and 278 (14.3%), respectively, in AREDS and 643 (38.0%), 402 (24.6%), and 341 (20.1%) in AREDS2. The hazard ratios of progression in quintile 5 (highest propensity for aspirin use) versus 1 (reference) were 1.17 (P = 0.35), 1.24 (0.25), and 0.95 (0.81), respectively, in AREDS and 1.26 (0.09), 1.46 (0.03), and 1.12 (0.58) in AREDS2. No significant association with progression to late AMD was observed for quintiles 2 through 5 for any of the 3 outcomes in either study. CONCLUSIONS:Aspirin use was not associated significantly with progression to late AMD or its subtypes in either the AREDS or AREDS2. Patients with AMD need not avoid aspirin for this reason when its use is medically indicated. Published by Elsevier Inc.
RCT Entities:
PURPOSE: To analyze the potential association between aspirin use and progression of age-related macular degeneration (AMD). DESIGN: Two prospective cohort studies within 2 controlled clinical trials of oral supplementation for age-related eye disease. PARTICIPANTS: Age-Related Eye Disease Study (AREDS) participants 55 to 80 years of age and AREDS2 participants 50 to 85 years of age. METHODS: Propensity scores for aspirin use were calculated for AREDS and AREDS2 participants separately by logistic regression. Of the participants without late AMD (geographic atrophy [GA] or neovascular AMD) in either eye at study baseline, aspirin users were matched 1:1 with nonusers by propensity score (separately for AREDS and AREDS2). Proportional hazards regression was performed, adjusting for age, on the matched participants to evaluate associations between aspirin propensity score and progression to late AMD (and its subtypes). MAIN OUTCOME MEASURES: Progression to late AMD on color fundus photographs, graded centrally. RESULTS: Of the 3734 eligible AREDS participants, 1049 (28.1%) were taking aspirin, and of the 2403 eligible AREDS2 participants, 1198 (49.9%) were taking aspirin. After matching by propensity score, the characteristics of the users and nonusers were similar in both studies. Of the 1950 matched AREDS participants and 1694 matched AREDS2 participants, over a median follow-up of 10.1 years and 5.0 years, respectively, the numbers who progressed to late AMD, GA, or neovascular AMD were 454 (23.3%), 345 (17.7%), and 278 (14.3%), respectively, in AREDS and 643 (38.0%), 402 (24.6%), and 341 (20.1%) in AREDS2. The hazard ratios of progression in quintile 5 (highest propensity for aspirin use) versus 1 (reference) were 1.17 (P = 0.35), 1.24 (0.25), and 0.95 (0.81), respectively, in AREDS and 1.26 (0.09), 1.46 (0.03), and 1.12 (0.58) in AREDS2. No significant association with progression to late AMD was observed for quintiles 2 through 5 for any of the 3 outcomes in either study. CONCLUSIONS:Aspirin use was not associated significantly with progression to late AMD or its subtypes in either the AREDS or AREDS2. Patients with AMD need not avoid aspirin for this reason when its use is medically indicated. Published by Elsevier Inc.
Authors: Chun Shing Kwok; Ashkan Shoamanesh; Hannah Charlotte Copley; Phyo Kyaw Myint; Yoon K Loke; Oscar R Benavente Journal: Stroke Date: 2015-02-26 Impact factor: 7.914
Authors: Lars G Fritsche; Robert N Fariss; Dwight Stambolian; Gonçalo R Abecasis; Christine A Curcio; Anand Swaroop Journal: Annu Rev Genomics Hum Genet Date: 2014-04-16 Impact factor: 8.929
Authors: Frederick L Ferris; C P Wilkinson; Alan Bird; Usha Chakravarthy; Emily Chew; Karl Csaky; SriniVas R Sadda Journal: Ophthalmology Date: 2013-01-16 Impact factor: 12.079
Authors: Gui-Shuang Ying; Maureen G Maguire; Ebenezer Daniel; Juan E Grunwald; Osama Ahmed; Daniel F Martin Journal: Ophthalmology Date: 2015-11-04 Impact factor: 12.079
Authors: John J McNeil; Rory Wolfe; Robyn L Woods; Andrew M Tonkin; Geoffrey A Donnan; Mark R Nelson; Christopher M Reid; Jessica E Lockery; Brenda Kirpach; Elsdon Storey; Raj C Shah; Jeff D Williamson; Karen L Margolis; Michael E Ernst; Walter P Abhayaratna; Nigel Stocks; Sharyn M Fitzgerald; Suzanne G Orchard; Ruth E Trevaks; Lawrence J Beilin; Colin I Johnston; Joanne Ryan; Barbara Radziszewska; Michael Jelinek; Mobin Malik; Charles B Eaton; Donna Brauer; Geoff Cloud; Erica M Wood; Suzanne E Mahady; Suzanne Satterfield; Richard Grimm; Anne M Murray Journal: N Engl J Med Date: 2018-09-16 Impact factor: 91.245
Authors: Lars G Fritsche; Wilmar Igl; Jessica N Cooke Bailey; Felix Grassmann; Sebanti Sengupta; Jennifer L Bragg-Gresham; Kathryn P Burdon; Scott J Hebbring; Cindy Wen; Mathias Gorski; Ivana K Kim; David Cho; Donald Zack; Eric Souied; Hendrik P N Scholl; Elisa Bala; Kristine E Lee; David J Hunter; Rebecca J Sardell; Paul Mitchell; Joanna E Merriam; Valentina Cipriani; Joshua D Hoffman; Tina Schick; Yara T E Lechanteur; Robyn H Guymer; Matthew P Johnson; Yingda Jiang; Chloe M Stanton; Gabriëlle H S Buitendijk; Xiaowei Zhan; Alan M Kwong; Alexis Boleda; Matthew Brooks; Linn Gieser; Rinki Ratnapriya; Kari E Branham; Johanna R Foerster; John R Heckenlively; Mohammad I Othman; Brendan J Vote; Helena Hai Liang; Emmanuelle Souzeau; Ian L McAllister; Timothy Isaacs; Janette Hall; Stewart Lake; David A Mackey; Ian J Constable; Jamie E Craig; Terrie E Kitchner; Zhenglin Yang; Zhiguang Su; Hongrong Luo; Daniel Chen; Hong Ouyang; Ken Flagg; Danni Lin; Guanping Mao; Henry Ferreyra; Klaus Stark; Claudia N von Strachwitz; Armin Wolf; Caroline Brandl; Guenther Rudolph; Matthias Olden; Margaux A Morrison; Denise J Morgan; Matthew Schu; Jeeyun Ahn; Giuliana Silvestri; Evangelia E Tsironi; Kyu Hyung Park; Lindsay A Farrer; Anton Orlin; Alexander Brucker; Mingyao Li; Christine A Curcio; Saddek Mohand-Saïd; José-Alain Sahel; Isabelle Audo; Mustapha Benchaboune; Angela J Cree; Christina A Rennie; Srinivas V Goverdhan; Michelle Grunin; Shira Hagbi-Levi; Peter Campochiaro; Nicholas Katsanis; Frank G Holz; Frédéric Blond; Hélène Blanché; Jean-François Deleuze; Robert P Igo; Barbara Truitt; Neal S Peachey; Stacy M Meuer; Chelsea E Myers; Emily L Moore; Ronald Klein; Michael A Hauser; Eric A Postel; Monique D Courtenay; Stephen G Schwartz; Jaclyn L Kovach; William K Scott; Gerald Liew; Ava G Tan; Bamini Gopinath; John C Merriam; R Theodore Smith; Jane C Khan; Humma Shahid; Anthony T Moore; J Allie McGrath; Reneé Laux; Milam A Brantley; Anita Agarwal; Lebriz Ersoy; Albert Caramoy; Thomas Langmann; Nicole T M Saksens; Eiko K de Jong; Carel B Hoyng; Melinda S Cain; Andrea J Richardson; Tammy M Martin; John Blangero; Daniel E Weeks; Bal Dhillon; Cornelia M van Duijn; Kimberly F Doheny; Jane Romm; Caroline C W Klaver; Caroline Hayward; Michael B Gorin; Michael L Klein; Paul N Baird; Anneke I den Hollander; Sascha Fauser; John R W Yates; Rando Allikmets; Jie Jin Wang; Debra A Schaumberg; Barbara E K Klein; Stephanie A Hagstrom; Itay Chowers; Andrew J Lotery; Thierry Léveillard; Kang Zhang; Murray H Brilliant; Alex W Hewitt; Anand Swaroop; Emily Y Chew; Margaret A Pericak-Vance; Margaret DeAngelis; Dwight Stambolian; Jonathan L Haines; Sudha K Iyengar; Bernhard H F Weber; Gonçalo R Abecasis; Iris M Heid Journal: Nat Genet Date: 2015-12-21 Impact factor: 38.330
Authors: Argentina Ornelas; Niki Zacharias-Millward; David G Menter; Jennifer S Davis; Lenard Lichtenberger; David Hawke; Ernest Hawk; Eduardo Vilar; Pratip Bhattacharya; Steven Millward Journal: Cancer Metastasis Rev Date: 2017-06 Impact factor: 9.264
Authors: Delu Song; Peiying Hua; Brian L VanderBeek; Joshua L Dunaief; Juan E Grunwald; Ebenezer Daniel; Maureen G Maguire; Daniel F Martin; Gui-Shuang Ying Journal: Retina Date: 2021-07-01 Impact factor: 3.975
Authors: Liubov D Robman; Le Thi Phuong Thao; Robyn H Guymer; Rory Wolfe; Robyn L Woods; Lauren Ab Hodgson; James Phung; Galina A Makeyeva; Y-Anh Le-Pham; Suzanne G Orchard; Jewhara Suleiman; Emily Maguire; Ruth E Trevaks; Stephanie A Ward; Moeen Riaz; Paul Lacaze; Elsdon Storey; Walter P Abhayaratna; Mark R Nelson; Michael E Ernst; Christopher M Reid; John J McNeil Journal: Contemp Clin Trials Commun Date: 2020-10-11